T cell anergy, exhaustion, senescence, and stemness in the tumor microenvironment
Open accessAbstract
Human tumors progress despite the presence of tumor associated antigen (TAA)-specific T cells. Many different molecular and cellular mechanisms contribute to the failure of T cells to eradicate the tumor. These include immune suppressive networks that impair ongoing T cell function and enable tumor escape. Recent studies have started to reveal the nature of effector T cells in the tumor microenvironment. In this article we discuss T cell anergy, exhaustion, senescence, and stemness, and review the phenotype of dysfunctional T cell subsets and the underlying molecular mechanisms in the tumor microenvironments. We suggest that targeting T cell dysfunctional mechanisms and introducing/promoting T cell stemness are important approaches to treat patients with cancer.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
0 of 115 cited sources checked · 0 supported · 0 flagged
- Premisecitation
There is evidence of antigen-specific, T cell-intrinsic dysfunction in the tumor microenvironment.
“There is evidence indicating antigen specific, T cell-intrinsic dysfunction in the tumor microenvironment [15,16].”
Quote in the paperSubstantial claim0 of 2 sources checked- cites [15] Nazareth MR Broderick L Simpson-Abelson MR Kelleher RJ Jr Yokota SJ Bankert RB Characterization of human lung tumor-associated fibroblasts and their ability to modulate the activation of tumor-associated T cells J Immunol 2007 178 5552 5562 17442937 source
Not checked in the free run.
- cites [16] Broderick L Brooks SP Takita H Baer AN Bernstein JM Bankert RB IL-12 reverses anergy to T cell receptor triggering in human lung tumor-associated memory T cells Clin Immunol 2006 118 159 169 16271513 source
Not checked in the free run.
- Interpretationreasoning
The B7 family imbalance creates a poor co-stimulatory, high co-inhibitory environment that promotes T cell anergy.
“This indicates a poor co-stimulatory, high co-inhibitory and therefore anergy-promoting environment.”
Quote in the paperSubstantial claim - Interpretationreasoning
T cell exhaustion may be a layered or progressive process resulting from repeated activation.
“T cell exhaustion may be a layered or progressive process to which T cells fall upon repeated activation.”
Quote in the paperNot a substantial claim - Premisecitation
In persistent disease settings such as chronic infection and malignancies, T cells acquire multiple inhibitory surface molecules that effectively prevent T cell activation.
“T cells acquiring multiple inhibitory surface molecules in persistent disease settings such as chronic infection [37,38] and malignancies [30,**39,40], which effectively prevent T cell activation.”
Quote in the paperSubstantial claim0 of 3 sources checked- cites [37] Wherry EJ Ha SJ Kaech SM Haining WN Sarkar S Kalia V Subramaniam S Blattman JN Barber DL Ahmed R Molecular signature of CD8+ T cell exhaustion during chronic viral infection Immunity 2007 27 670 684 17950003 source
Not checked in the free run.
- cites [38] Blackburn SD Shin H Haining WN Zou T Workman CJ Polley A Betts MR Freeman GJ Vignali DA Wherry EJ Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection Nat Immunol 2009 10 29 37 19043418 PMC2605166 source
Not checked in the free run.
- cites [30,**39,40]
Not checked in the free run.
- Interpretationnone given
Tumor-induced T cell anergy may be one of the immune evasion mechanisms in patients with cancer.
“In summary, tumor induced T cell anergy may be one of the immune evasion mechanisms in patients with cancer.”
Quote in the paperNot a substantial claim
- Interpretationreasoning
T cell anergy may be a functional mechanism in patients with cancer.
“Therefore, T cell anergy may be a functional mechanism in patients with cancer.”
Quote in the paperSubstantial claim - Premisecitation
Inhibitory B7 family members are widely expressed by malignant cells and APCs in the human tumor microenvironment.
“Given that members of the inhibitory B7 family are widely expressed by malignant cells and APCs within the human tumor microenvironment [7]”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [7] Zou W Chen L Inhibitory B7-family molecules in the tumour microenvironment Nat Rev Immunol 2008 8 467 477 18500231 source
Not checked in the free run.
- Premisecitation
T cells that receive antigen with suboptimal CD28 co-stimulation and/or high co-inhibition become anergic, with low IL-2 production and G1/S cell cycle arrest.
“It is generally accepted that T cells that are presented antigen along with suboptimal CD28 co-stimulation [4,5] and/or high co-inhibition [17] result in anergic phenotypes, as characterized by their low IL-2 production and cell cycle arrest at the G1/S phase.”
Quote in the paperNot a substantial claim0 of 3 sources checked- cites [4] Schwartz RH A cell culture model for T lymphocyte clonal anergy Science 1990 248 1349 1356 2113314 source
Not checked in the free run.
- cites [5] Schwartz RH T cell anergy Annu Rev Immunol 2003 21 305 334 12471050 source
Not checked in the free run.
- cites [17] Greenwald RJ Boussiotis VA Lorsbach RB Abbas AK Sharpe AH CTLA-4 regulates induction of anergy in vivo Immunity 2001 14 145 155 11239447 source
Not checked in the free run.
- Premisecitation
Exhausted CD8+ T cells have been found in patients with melanoma, ovarian cancer, and hepatocellular carcinoma.
“Exhausted CD8+ T cells were found in patients with melanoma [*31], ovarian cancer [9] and hepatocellular carcinoma (HCC) [30].”
Quote in the paperNot a substantial claim0 of 3 sources checked- cites [*31]
Not checked in the free run.
- cites [9] source
Not checked in the free run.
- cites [30] Wu K Kryczek I Chen L Zou W Welling TH Kupffer cell suppression of CD8+ T cells in human hepatocellular carcinoma is mediated by B7-H1/programmed death-1 interactions Cancer Res 2009 69 8067 8075 19826049 PMC4397483 source
Not checked in the free run.
- Premisecitation
Recruitment of SHP-1 and/or SHP-2 to the ITSM in the PD-1 cytoplasmic tail inhibits signaling, particularly PI3K/AKT activation downstream of the T-cell receptor, causing T cell dysfunction.
“it is suggested that recruitment of SH2-domain containing protein tyrosine phosphatases (SHP-1 and/or SHP-2) to the immunoreceptor tyrosine-based switch motif (ITSM) within the PD-1 cytoplasmic tail inhibits signaling events, particularly PI3K/AKT activation, downstream signals of the T-cell receptor [34], and in turn results in T cell dysfunction.”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [34] Riley JL PD-1 signaling in primary T cells Immunol Rev 2009 229 114 125 19426218 PMC3424066 source
Not checked in the free run.
- Premisecitation
Epigenetic factors including IKAROS (via acetylation) and Sirt1 participate in histone modifications that promote T cell anergy.
“Epigenetic factors such as IKAROS (through acetylation) [25] and Sirt1 are involved in histone modifications that promote T cell anergy [26,27].”
Quote in the paperNot a substantial claim0 of 3 sources checked- cites [25] Thomas RM Chunder N Chen C Umetsu SE Winandy S Wells AD Ikaros enforces the costimulatory requirement for IL2 gene expression and is required for anergy induction in CD4+ T lymphocytes J Immunol 2007 179 7305 7315 18025173 source
Not checked in the free run.
- cites [26] Gao B Kong Q Kemp K Zhao YS Fang D Analysis of sirtuin 1 expression reveals a molecular explanation of IL-2-mediated reversal of T-cell tolerance Proc Natl Acad Sci U S A 2012 109 899 904 22219356 PMC3271862 source
Not checked in the free run.
- cites [27] Bandyopadhyay S Dure M Paroder M Soto-Nieves N Puga I Macian F Interleukin 2 gene transcription is regulated by Ikaros-induced changes in histone acetylation in anergic T cells Blood 2007 109 2878 2886 17148585 PMC1852212 source
Not checked in the free run.
- Interpretationcitation
T cell anergy results from combined negative regulation of proximal TCR-coupled signal transduction and active transcriptional silencing reinforced by epigenetic mechanisms.
“Thus, anergy is the combined result of factors that negatively regulate proximal TCR-coupled signal transduction, together with a program of active transcriptional silencing that is reinforced through epigenetic mechanisms [6].”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [6] Wells AD New insights into the molecular basis of T cell anergy: anergy factors, avoidance sensors, and epigenetic imprinting J Immunol 2009 182 7331 7341 19494254 source
Not checked in the free run.
- Premisecitation
In the tumor microenvironment, stimulatory and inhibitory B7 family members are imbalanced, with high inhibitory and low stimulatory expression.
“There is an active imbalance between stimulatory and inhibitory B7 family members in the tumor microenvironment [1,3,7,8].”
- Also stated in: § T cell anergy · plain
“Human tumors and tumor associated antigen presenting cells (APCs) often express high levels of B7-H1 (CD274 or PD-L1), B7-H2 (CD275 or ICOS-L), B7-H3 (CD276), B7-H4 (B7S1 or B7x), and B7-DC (CD273 or PD-L2) with low-to-absent expression of B7-1 (CD80) and B7-2 (CD86) [7–10] (Fig. 2).”
Quote in the paperSubstantial claim0 of 6 sources checked- cites [1] Zou W Immunosuppressive networks in the tumour environment and their therapeutic relevance Nat Rev Cancer 2005 5 263 274 15776005 source
Not checked in the free run.
- cites [3] Pardoll DM The blockade of immune checkpoints in cancer immunotherapy Nat Rev Cancer 2012 12 252 264 22437870 PMC4856023 source
Not checked in the free run.
- cites [7] Zou W Chen L Inhibitory B7-family molecules in the tumour microenvironment Nat Rev Immunol 2008 8 467 477 18500231 source
Not checked in the free run.
- cites [8] Blank C Brown I Peterson AC Spiotto M Iwai Y Honjo T Gajewski TF PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells Cancer Res 2004 64 1140 1145 14871849 source
Not checked in the free run.
- cites [9] source
Not checked in the free run.
- cites [10] Kryczek I Zou L Rodriguez P Zhu G Wei S Mottram P Brumlik M Cheng P Curiel T Myers L B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma J Exp Med 2006 203 871 881 16606666 PMC2118300 source
Not checked in the free run.
- Also stated in: § T cell anergy · plain
- Premisecitation
TCR engagement by MHC alone causes Ca2+ imbalance and cytosolic retention of active RAP-1, which CD28 co-stimulation normally corrects.
“Specifically, sole binding of TCR by MHC promotes Ca2+ imbalance on T cells and retention of active-RAP-1 in the cytosol, an imbalance that would normally be corrected by co-stimulation through CD28 (Ras/MAPK) [**19,20].”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [**19,20]
Not checked in the free run.
- Premisecitation
Recent clinical trials have validated that blockade of B7-H1/PD-1 signaling is a meaningful immune therapeutic regimen.
“Recent clinical trials have validated that blockade of B7-H1/PD-1 signaling is a meaningful immune therapeutic regimen [**32,**33].”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [**32,**33]
Not checked in the free run.
- Premisecitation
Egr2 may be a central transcription factor regulating T cell anergy.
“Early growth response gene 2 (Egr2) may be a central transcription factor that regulates T cell anergic state [*18].”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [*18]
Not checked in the free run.
- Premisecitation
Blockade of the B7-H1/PD-1 pathway has been investigated as a therapeutic target in solid human tumors.
“blockade of B7-H1/PD-1 pathway was investigated as therapeutic targets in solid human tumors [9,30]”
Quote in the paperNot a substantial claim0 of 2 sources checked- cites [9] source
Not checked in the free run.
- cites [30] Wu K Kryczek I Chen L Zou W Welling TH Kupffer cell suppression of CD8+ T cells in human hepatocellular carcinoma is mediated by B7-H1/programmed death-1 interactions Cancer Res 2009 69 8067 8075 19826049 PMC4397483 source
Not checked in the free run.
- Premisecitation
Galectin-9 is the ligand for Tim-3.
“Galectin-9 is the Tim-3 ligand.”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [65] Zhu C Anderson AC Schubart A Xiong H Imitola J Khoury SJ Zheng XX Strom TB Kuchroo VK The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity Nat Immunol 2005 6 1245 1252 16286920 source
Not checked in the free run.
- Premisecitation
Similar findings were obtained in patients with melanoma and lymphoma.
“Similar findings were obtained in patients with melanoma [*63] and lymphoma [64].”
Quote in the paperNot a substantial claim0 of 2 sources checked- cites [*63]
Not checked in the free run.
- cites [64] Huang X Bai X Cao Y Wu J Huang M Tang D Tao S Zhu T Liu Y Yang Y Lymphoma endothelium preferentially expresses Tim-3 and facilitates the progression of lymphoma by mediating immune evasion J Exp Med 2010 207 505 520 20176801 PMC2839144 source
Not checked in the free run.
- Premisecitation
High levels of senescent T cells are found in younger patients with autoimmune disease and chronic viral infection.
“However, high levels of senescent T cells were found in younger patients with autoimmune disease and chronic viral infection [54].”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [54] Pawelec G Solana R Immunoageing - the cause or effect of morbidity Trends Immunol 2001 22 348 349 11505929 source
Not checked in the free run.
- Premisecitation
High expression of Tim-3, CD57, and KLRG-1, in addition to low CD28, is thought to be associated with T cell senescence.
“In addition to low expression of CD28, high expression of Tim-3, CD57, killer cell lectin-like receptor subfamily G, member 1 (KLRG-1) are thought to be associated with T cell senescence [40,60–64](Fig. 2).”
Quote in the paperNot a substantial claim0 of 6 sources checked- cites [40] Li H Wu K Tao K Chen L Zheng Q Lu X Liu J Shi L Liu C Wang G Tim-3/galectin-9 signaling pathway mediates T-cell dysfunction and predicts poor prognosis in patients with hepatitis B virus-associated hepatocellular carcinoma Hepatology 2012 56 1342 1351 22505239 source
Not checked in the free run.
- cites [60] Brenchley JM Karandikar NJ Betts MR Ambrozak DR Hill BJ Crotty LE Casazza JP Kuruppu J Migueles SA Connors M Expression of CD57 defines replicative senescence and antigen-induced apoptotic death of CD8+ T cells Blood 2003 101 2711 2720 12433688 source
Not checked in the free run.
- cites [61] source
Not checked in the free run.
- cites [62] Voehringer D Blaser C Brawand P Raulet DH Hanke T Pircher H Viral infections induce abundant numbers of senescent CD8 T cells J Immunol 2001 167 4838 4843 11673487 source
Not checked in the free run.
- cites [63] source
Not checked in the free run.
- cites [64] Huang X Bai X Cao Y Wu J Huang M Tang D Tao S Zhu T Liu Y Yang Y Lymphoma endothelium preferentially expresses Tim-3 and facilitates the progression of lymphoma by mediating immune evasion J Exp Med 2010 207 505 520 20176801 PMC2839144 source
Not checked in the free run.
- Premisecitation
Tumor cells can induce T cell senescence in in vitro co-cultures.
“In line with this notion, tumor cells can induce T cell senescence in in vitro co-cultures [56].”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [56] Montes CL Chapoval AI Nelson J Orhue V Zhang X Schulze DH Strome SE Gastman BR Tumor-induced senescent T cells with suppressor function: a potential form of tumor immune evasion Cancer Res 2008 68 870 879 18245489 source
Not checked in the free run.
- Premisecitation
In patients with hepatocellular carcinoma, PD-1 and Tim-3 expression minimally overlaps in tumor-infiltrating T cells.
“in patients with HCC, the expression of PD-1 and Tim-3 is minimally overlapping in tumor infiltrating T cells.”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [40] Li H Wu K Tao K Chen L Zheng Q Lu X Liu J Shi L Liu C Wang G Tim-3/galectin-9 signaling pathway mediates T-cell dysfunction and predicts poor prognosis in patients with hepatitis B virus-associated hepatocellular carcinoma Hepatology 2012 56 1342 1351 22505239 source
Not checked in the free run.
- Premisecitation
Exhausted T cells may highly express multiple inhibitory receptors, including PD-1, 2B4, BTLA, CTLA-4, CD160, LAG-3, and Tim-3.
“Notably, exhausted T cells may highly express multiple “inhibitory” receptors, including PD-1, 2B4 (CD244), BTLA, CTLA-4, CD160, LAG-3 and Tim-3 [38,42,43,45].”
Quote in the paperNot a substantial claim0 of 4 sources checked- cites [38] Blackburn SD Shin H Haining WN Zou T Workman CJ Polley A Betts MR Freeman GJ Vignali DA Wherry EJ Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection Nat Immunol 2009 10 29 37 19043418 PMC2605166 source
Not checked in the free run.
- cites [42] Fourcade J Sun Z Pagliano O Guillaume P Luescher IF Sander C Kirkwood JM Olive D Kuchroo V Zarour HM CD8(+) T cells specific for tumor antigens can be rendered dysfunctional by the tumor microenvironment through upregulation of the inhibitory receptors BTLA and PD-1 Cancer Res 2012 72 887 896 22205715 PMC3288235 source
Not checked in the free run.
- cites [43] Derre L Rivals JP Jandus C Pastor S Rimoldi D Romero P Michielin O Olive D Speiser DE BTLA mediates inhibition of human tumor-specific CD8+ T cells that can be partially reversed by vaccination J Clin Invest 2010 120 157 167 20038811 PMC2799219 source
Not checked in the free run.
- cites [45] Woo SR Turnis ME Goldberg MV Bankoti J Selby M Nirschl CJ Bettini ML Gravano DM Vogel P Liu CL Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape Cancer Res 2012 72 917 927 22186141 PMC3288154 source
Not checked in the free run.
- Premisecitation
Blockade of Tim-3 and PD-1 rescues effector functions, shown by cell cycle progression and acquired effector cytokine expression and cytotoxicity.
“blockade of these surface molecules allows rescue of their effector functions as shown by cell cycle progression and acquired effector cytokine expression and cytotoxicity [40,43,44].”
Quote in the paperSubstantial claim0 of 3 sources checked- cites [40] Li H Wu K Tao K Chen L Zheng Q Lu X Liu J Shi L Liu C Wang G Tim-3/galectin-9 signaling pathway mediates T-cell dysfunction and predicts poor prognosis in patients with hepatitis B virus-associated hepatocellular carcinoma Hepatology 2012 56 1342 1351 22505239 source
Not checked in the free run.
- cites [43] Derre L Rivals JP Jandus C Pastor S Rimoldi D Romero P Michielin O Olive D Speiser DE BTLA mediates inhibition of human tumor-specific CD8+ T cells that can be partially reversed by vaccination J Clin Invest 2010 120 157 167 20038811 PMC2799219 source
Not checked in the free run.
- cites [44] Jin HT Anderson AC Tan WG West EE Ha SJ Araki K Freeman GJ Kuchroo VK Ahmed R Cooperation of Tim-3 and PD-1 in CD8 T-cell exhaustion during chronic viral infection Proc Natl Acad Sci U S A 2010 107 14733 14738 20679213 PMC2930455 source
Not checked in the free run.
- Interpretationcitation
Certain subsets of memory T cells have the capability both to self-renew and to generate more effector T cells.
“These studies support the concept that certain subsets of memory T cells endow the capability both to self-renew and to generate more effector T cells.”
Quote in the paperSubstantial claim - Premisecitation
In more recent mouse work, blocking T cell differentiation via Wnt signaling promoted generation of the memory stem cell population.
“More recent mouse work has shown that by blocking T cell differentiation, Wnt signaling promoted the generation of this memory stem cell population [70].”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [70] Gattinoni L Zhong XS Palmer DC Ji Y Hinrichs CS Yu Z Wrzesinski C Boni A Cassard L Garvin LM Wnt signaling arrests effector T cell differentiation and generates CD8+ memory stem cells Nat Med 2009 15 808 813 19525962 PMC2707501 source
Not checked in the free run.
- Interpretationcitation
The capacity to continuously generate effector memory T cells replenishes the effector memory T cell pool and helps maintain a constant memory T cell repertoire for a human lifetime, despite finite effector cell lifespan and reduced thymus function.
“The capacity to continuously generate effector memory T cells will replenish the effector memory T cell pool, and help maintain a constant repertoire of memory T cells for a human lifetime, despite the finite lifespan of individual effector cells and reduced thymus function [68].”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [68] Lanzavecchia A Sallusto F Progressive differentiation and selection of the fittest in the immune response Nat Rev Immunol 2002 2 982 987 12461571 source
Not checked in the free run.
- Premisecitation
DNA damage can cause mouse thymic precursor lymphocytes to withdraw from the cell cycle and undergo senescence.
“DNA damage can cause mouse thymic precursor lymphocytes to withdraw from the cell cycle and undergo senescence [59].”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [59] Van Nguyen T Puebla-Osorio N Pang H Dujka ME Zhu C DNA damage-induced cellular senescence is sufficient to suppress tumorigenesis: a mouse model J Exp Med 2007 204 1453 1461 17535972 PMC2118600 source
Not checked in the free run.
- Interpretationnone given
Peripheral T cell tolerance mechanisms, including regulatory T cells, anergy, exhaustion, and senescence, weaken ongoing T cell immunity.
“In conclusion, peripheral T cell tolerance mechanisms including regulatory T cells, T cell anergy, exhaustion, and senescence impair ongoing T cell immunity and enable tumor immune escape.”
Quote in the paperSubstantial claim - Interpretationreasoning
These same peripheral T cell tolerance mechanisms enable tumors to escape immune attack.
“In conclusion, peripheral T cell tolerance mechanisms including regulatory T cells, T cell anergy, exhaustion, and senescence impair ongoing T cell immunity and enable tumor immune escape.”
Quote in the paperSubstantial claim - Interpretationreasoning
Although conceptually distinct, these T cell subsets may be functionally and phenotypically overlapped.
“Although these cell subsets are conceptually distinct, they may be functionally and phenotypically overlapped.”
Quote in the paperSubstantial claim - Interpretationnone given
Compelling evidence demonstrates that T cell anergy, exhaustion, senescence, and stemness co-exist in the tumor microenvironment.
“Compelling evidence demonstrates the co-existence of T cell anergy, exhaustion, senescence and stemness in the tumor microenvironment.”
Quote in the paperSubstantial claim - Interpretationcitation
Different categories of T cell abnormalities may be mechanistically intertwined.
“It suggests that different categories of T cell abnormalities may be mechanistically intertwined [28,74–76].”
Quote in the paperSubstantial claim0 of 4 sources checked- cites [28] Wherry EJ T cell exhaustion Nat Immunol 2011 12 492 499 21739672 source
Not checked in the free run.
- cites [74] Workman CJ Cauley LS Kim IJ Blackman MA Woodland DL Vignali DA Lymphocyte activation gene-3 (CD223) regulates the size of the expanding T cell population following antigen activation in vivo J Immunol 2004 172 5450 5455 15100286 source
Not checked in the free run.
- cites [75] Huang CT Workman CJ Flies D Pan X Marson AL Zhou G Hipkiss EL Ravi S Kowalski J Levitsky HI Role of LAG-3 in regulatory T cells Immunity 2004 21 503 513 15485628 source
Not checked in the free run.
- cites [76] Bengsch B Seigel B Ruhl M Timm J Kuntz M Blum HE Pircher H Thimme R Coexpression of PD-1, 2B4, CD160 and KLRG1 on exhausted HCV-specific CD8+ T cells is linked to antigen recognition and T cell differentiation PLoS Pathog 2010 6 e1000947 20548953 PMC2883597 source
Not checked in the free run.
- Premisecitation
Th17 cells achieve a higher anti-tumor response compared to effector and central memory T cells.
“Furthermore, these cells achieved a higher anti-tumor response when compared to effector and central memory T cells.”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [**71,**72]
Not checked in the free run.
- Interpretationreasoning
Stemness might correlate with better immune responses.
“suggesting that stemness might correlate with better immune responses.”
Quote in the paperSubstantial claim - Premisecitation
Dysfunctional T cells express, to different degrees, inhibitory molecules including PD-1, Tim-3, LAG-3, 2B4, CD160, and KLRG-1.
“compelling evidence indicate that dysfunctional T cells express in different degrees the “inhibitory” molecules including PD-1, Tim-3, LAG-3, 2B4, CD160, and KLGR-1.”
Quote in the paperSubstantial claim0 of 4 sources checked- cites [28] Wherry EJ T cell exhaustion Nat Immunol 2011 12 492 499 21739672 source
Not checked in the free run.
- cites [74] Workman CJ Cauley LS Kim IJ Blackman MA Woodland DL Vignali DA Lymphocyte activation gene-3 (CD223) regulates the size of the expanding T cell population following antigen activation in vivo J Immunol 2004 172 5450 5455 15100286 source
Not checked in the free run.
- cites [75] Huang CT Workman CJ Flies D Pan X Marson AL Zhou G Hipkiss EL Ravi S Kowalski J Levitsky HI Role of LAG-3 in regulatory T cells Immunity 2004 21 503 513 15485628 source
Not checked in the free run.
- cites [76] Bengsch B Seigel B Ruhl M Timm J Kuntz M Blum HE Pircher H Thimme R Coexpression of PD-1, 2B4, CD160 and KLRG1 on exhausted HCV-specific CD8+ T cells is linked to antigen recognition and T cell differentiation PLoS Pathog 2010 6 e1000947 20548953 PMC2883597 source
Not checked in the free run.
- Premisecitation
Despite phenotypic markers of terminal differentiation, Th17 cells have stem cell features and powerful functionalities.
“For example, despite their phenotypic markers of terminal differentiation, Th17 cells have stem cell feature with powerful functionalities [71–73].”
Quote in the paperSubstantial claim0 of 3 sources checked
- May combine two claims. 29
- Classified as probably not a substantial claim. 4
May combine two claims.
PremisecitationIn mouse studies, B7-H1/PD-1 signaling was proposed to mediate CD8+ T cell functional exhaustion in chronic infection, and PD-1 was proposed as a marker for exhausted T cells.
“Initial mouse studies have proposed that B7-H1/PD-1 signaling pathway mediates CD8+ T cell functional exhaustion in the context of chronic infection, and PD-1 was proposed to be a marker for exhausted T cells [*29].”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [*29]
Not checked in the free run.
May combine two claims.
PremisecitationActivated T cells and early-stage effector T cells may express PD-1 and remain functional.
“Notably, activated T cells and effector T cells in the early stage may express PD-1 and remain functional [35,*36].”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [35,*36]
Not checked in the free run.
Probably not a substantial claim: may not pass S3 (load-bearing).
PremisecitationThe anergy program is initiated by improper mTOR and Ras/MAPK signaling downstream of TCR/CD28 engagement.
“It has been suggested that the anergy program is initiated by improper mTOR and Ras/MAPK signaling in the cell, a pathway which lies directly downstream of TCR/CD28 engagement.”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [**19,20]
Not checked in the free run.
May combine two claims.
PremisecitationIn animal models, introducing B7-1 into tumors or blocking inhibitory B7 family members reduces tumor growth or causes spontaneous tumor rejection.
“Animal model studies have shown that introduction of B7-1 into tumors by transfection or blockade of inhibitory B7 family members can reduce tumor growth or result in spontaneous tumor rejection in vivo [7–13].”
Quote in the paperSubstantial claim0 of 7 sources checked- cites [7] Zou W Chen L Inhibitory B7-family molecules in the tumour microenvironment Nat Rev Immunol 2008 8 467 477 18500231 source
Not checked in the free run.
- cites [8] Blank C Brown I Peterson AC Spiotto M Iwai Y Honjo T Gajewski TF PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells Cancer Res 2004 64 1140 1145 14871849 source
Not checked in the free run.
- cites [9] source
Not checked in the free run.
- cites [10] Kryczek I Zou L Rodriguez P Zhu G Wei S Mottram P Brumlik M Cheng P Curiel T Myers L B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma J Exp Med 2006 203 871 881 16606666 PMC2118300 source
Not checked in the free run.
- cites [11] Chen L Ashe S Brady WA Hellstrom I Hellstrom KE Ledbetter JA McGowan P Linsley PS Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4 Cell 1992 71 1093 1102 1335364 source
Not checked in the free run.
- cites [12] Gajewski TF B7-1 but not B7-2 efficiently costimulates CD8+ T lymphocytes in the P815 tumor system in vitro J Immunol 1996 156 465 472 8543795 source
Not checked in the free run.
- cites [13] Blank C Kuball J Voelkl S Wiendl H Becker B Walter B Majdic O Gajewski TF Theobald M Andreesen R Blockade of PD-L1 (B7-H1) augments human tumor-specific T cell responses in vitro Int J Cancer 2006 119 317 327 16482562 source
Not checked in the free run.
May combine two claims.
PremisecitationHuman tumor cells and/or tumor-associated APCs express B7-H1, and the B7-H1/PD-1 pathway mediates immune suppression.
“it was demonstrated that human tumor cells and/or tumor associated APCs expressed B7-H1, and B7-H1/PD-1 pathway mediated immune suppression [**9]”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [**9]
Not checked in the free run.
May combine two claims.
PremisecitationTim-3, LAG-3, and BTLA are co-expressed with PD-1, and this co-expression strongly correlates with immune dysfunction in cancer patients.
“In the course of defining exhausted PD-1+ T cells, T cell immunoglobulin and mucin-domain-containing molecule-3 (Tim-3) [39,41], lymphocyte-activation gene (LAG)-3 [38], and the B and T-cell lymphocyte attenuator (BTLA, CD272) [42,43] were found to be co-expressed with PD-1, and the co-expression has been strongly correlated with immune dysfunction in patients with cancer.”
Quote in the paperSubstantial claim0 of 5 sources checked- cites [39] source
Not checked in the free run.
- cites [41] Zhou Q Munger ME Veenstra RG Weigel BJ Hirashima M Munn DH Murphy WJ Azuma M Anderson AC Kuchroo VK Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia Blood 2011 117 4501 4510 21385853 PMC3099570 source
Not checked in the free run.
- cites [38] Blackburn SD Shin H Haining WN Zou T Workman CJ Polley A Betts MR Freeman GJ Vignali DA Wherry EJ Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection Nat Immunol 2009 10 29 37 19043418 PMC2605166 source
Not checked in the free run.
- cites [42] Fourcade J Sun Z Pagliano O Guillaume P Luescher IF Sander C Kirkwood JM Olive D Kuchroo V Zarour HM CD8(+) T cells specific for tumor antigens can be rendered dysfunctional by the tumor microenvironment through upregulation of the inhibitory receptors BTLA and PD-1 Cancer Res 2012 72 887 896 22205715 PMC3288235 source
Not checked in the free run.
- cites [43] Derre L Rivals JP Jandus C Pastor S Rimoldi D Romero P Michielin O Olive D Speiser DE BTLA mediates inhibition of human tumor-specific CD8+ T cells that can be partially reversed by vaccination J Clin Invest 2010 120 157 167 20038811 PMC2799219 source
Not checked in the free run.
May combine two claims.
PremisecitationThe E3 ubiquitin ligase family can affect PI3K, mTOR, and Ras/MAPK signaling and helps actively maintain anergy.
“The E3 ubiquiting ligase family can affect PI3K, mTOR, and Ras/MAPK signaling pathways and help to actively maintain anergy [21,23,24].”
Quote in the paperNot a substantial claim0 of 3 sources checked- cites [21] Anandasabapathy N Ford GS Bloom D Holness C Paragas V Seroogy C Skrenta H Hollenhorst M Fathman CG Soares L GRAIL: an E3 ubiquitin ligase that inhibits cytokine gene transcription is expressed in anergic CD4+ T cells Immunity 2003 18 535 547 12705856 source
Not checked in the free run.
- cites [23] Jeon MS Atfield A Venuprasad K Krawczyk C Sarao R Elly C Yang C Arya S Bachmaier K Su L Essential role of the E3 ubiquitin ligase Cbl-b in T cell anergy induction Immunity 2004 21 167 177 15308098 source
Not checked in the free run.
- cites [24] Mueller DL E3 ubiquitin ligases as T cell anergy factors Nat Immunol 2004 5 883 890 15334084 source
Not checked in the free run.
May combine two claims.
PremisecitationIn a lymphopenic host, homeostatic proliferation of anti-tumor T cells reverses anergy and promotes tumor rejection in vivo.
“Homeostatic proliferation of anti-tumor T cells in a lymphopenic host both reverses anergy and promotes tumor rejection in vivo [14].”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [14] Brown IE Blank C Kline J Kacha AK Gajewski TF Homeostatic proliferation as an isolated variable reverses CD8+ T cell anergy and promotes tumor rejection J Immunol 2006 177 4521 4529 16982889 source
Not checked in the free run.
Probably not a substantial claim: may not pass S1 (asserted), S3 (load-bearing).
PremisecitationThe genetic reprogramming effects of the Ca2+ imbalance are hypothesized to be mediated by NFAT homodimer formation and transcription of anergy-inducing genes.
“The effects of this imbalance on the genetic reprogramming of these cells have been hypothesized to be mediated by NFAT homodimer formation and transcription of anergy-inducing genes [21,22].”
Quote in the paperNot a substantial claim0 of 2 sources checked- cites [21] Anandasabapathy N Ford GS Bloom D Holness C Paragas V Seroogy C Skrenta H Hollenhorst M Fathman CG Soares L GRAIL: an E3 ubiquitin ligase that inhibits cytokine gene transcription is expressed in anergic CD4+ T cells Immunity 2003 18 535 547 12705856 source
Not checked in the free run.
- cites [22] Soto-Nieves N Puga I Abe BT Bandyopadhyay S Baine I Rao A Macian F Transcriptional complexes formed by NFAT dimers regulate the induction of T cell tolerance J Exp Med 2009 206 867 876 19307325 PMC2715123 source
Not checked in the free run.
May combine two claims.
PremisecitationHCC-associated Tim-3+ T cells express reduced CD28, suggesting they may be at an early senescence stage.
“HCC-associated Tim-3+T cells expressed reduced CD28, suggesting that these cells may be early senescence stage [40].”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [40] Li H Wu K Tao K Chen L Zheng Q Lu X Liu J Shi L Liu C Wang G Tim-3/galectin-9 signaling pathway mediates T-cell dysfunction and predicts poor prognosis in patients with hepatitis B virus-associated hepatocellular carcinoma Hepatology 2012 56 1342 1351 22505239 source
Not checked in the free run.
May combine two claims.
PremisecitationHuman tumor-associated Th17 cells express stem cell markers and exhibit stem cell-like features.
“In line with these limited reports in non-tumor system, human tumor associated Th17 cells expressed stem cell markers and exhibited stem cell like features.”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [**71,**72]
Not checked in the free run.
Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.
PremisecitationCell cycle controlling proteins p16, p21, and p53 normally inhibit cell cycle progression and accumulate in senescent cells.
“Cell cycle controlling proteins p16, p21, and p53, normally inhibit cell cycle progression and have been shown to be accumulated in senescent cells [49–51].”
Quote in the paperNot a substantial claim0 of 3 sources checked- cites [49] Passos JF Nelson G Wang C Richter T Simillion C Proctor CJ Miwa S Olijslagers S Hallinan J Wipat A Feedback between p21 and reactive oxygen production is necessary for cell senescence Mol Syst Biol 2010 6 347 20160708 PMC2835567 source
Not checked in the free run.
- cites [50] Rodier F Coppe JP Patil CK Hoeijmakers WA Munoz DP Raza SR Freund A Campeau E Davalos AR Campisi J Persistent DNA damage signalling triggers senescence-associated inflammatory cytokine secretion Nat Cell Biol 2009 11 973 979 19597488 PMC2743561 source
Not checked in the free run.
- cites [51] Beausejour CM Krtolica A Galimi F Narita M Lowe SW Yaswen P Campisi J Reversal of human cellular senescence: roles of the p53 and p16 pathways EMBO J 2003 22 4212 4222 12912919 PMC175806 source
Not checked in the free run.
May combine two claims.
PremisecitationTelomere shortening is an inherent byproduct of cell division that affects cellular function and leads to cell senescence.
“Telomere shortening is an inherent byproduct of cellular division, which affects cellular function and leads to cell senescence [48].”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [48] Hayflick L Moorhead PS The serial cultivation of human diploid cell strains Exp Cell Res 1961 25 585 621 13905658 source
Not checked in the free run.
May combine two claims.
PremisecitationMouse central memory T cells are arrested at a pre-differentiation stage by transcriptional inhibitors and retain replicative potential and long-term production of effector T cells after a second antigen challenge.
“The concept of T cell stemness was initially stemmed from the observations that mouse central memory T cells are arrested at a pre-differentiation stage by transcriptional inhibitors and retain replicative potential and long-term production of effector T cells after a second antigen challenge [67].”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [67] Fearon DT Manders P Wagner SD Arrested differentiation, the self-renewing memory lymphocyte, and vaccination Science 2001 293 248 250 11452114 source
Not checked in the free run.
May combine two claims.
PremisecitationBat3 localization at the Tim-3 cytoplasmic tail allows continued T cell proliferation and IFNγ production, an effect lost in Bat3-deficient cells and upon Tim-3 binding to galectin-9.
“Bat3 localization at this protein region allows T cells continued proliferation and IFNγ production, an effect that was lost on Bat3 deficient cells and upon Tim-3 binding to galectin-9.”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [66] Rangachari M Zhu C Sakuishi K Xiao S Karman J Chen A Angin M Wakeham A Greenfield EA Sobel RA Bat3 promotes T cell responses and autoimmunity by repressing Tim-3-mediated cell death and exhaustion Nat Med 2012 18 1394 1400 22863785 PMC3491118 source
Not checked in the free run.
May combine two claims.
PremisecitationT cells co-expressing these surface molecules show significant decrease in IL-2, IFNγ, and TNFα expression as well as cell cycle arrest, which defines T cell exhaustion.
“In these studies, T cells co-expressing these surface molecules show a significant decrease in IL-2, IFNγ, and TNFα expression as well as cell cycle arrest, which defines T cell exhaustion.”
Quote in the paperSubstantial claim0 of 5 sources checked- cites [39] source
Not checked in the free run.
- cites [41] Zhou Q Munger ME Veenstra RG Weigel BJ Hirashima M Munn DH Murphy WJ Azuma M Anderson AC Kuchroo VK Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia Blood 2011 117 4501 4510 21385853 PMC3099570 source
Not checked in the free run.
- cites [38] Blackburn SD Shin H Haining WN Zou T Workman CJ Polley A Betts MR Freeman GJ Vignali DA Wherry EJ Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection Nat Immunol 2009 10 29 37 19043418 PMC2605166 source
Not checked in the free run.
- cites [42] Fourcade J Sun Z Pagliano O Guillaume P Luescher IF Sander C Kirkwood JM Olive D Kuchroo V Zarour HM CD8(+) T cells specific for tumor antigens can be rendered dysfunctional by the tumor microenvironment through upregulation of the inhibitory receptors BTLA and PD-1 Cancer Res 2012 72 887 896 22205715 PMC3288235 source
Not checked in the free run.
- cites [43] Derre L Rivals JP Jandus C Pastor S Rimoldi D Romero P Michielin O Olive D Speiser DE BTLA mediates inhibition of human tumor-specific CD8+ T cells that can be partially reversed by vaccination J Clin Invest 2010 120 157 167 20038811 PMC2799219 source
Not checked in the free run.
May combine two claims.
InterpretationcitationCancer-associated Tim-3+ T cells may contain senescent cells and experience cell cycle arrest in G1/S phase.
“It suggests that cancer associated Tim-3+ T cells may contain senescent cells and experience cell cycle arrest in G1/S phase.”
Quote in the paperSubstantial claimMay combine two claims.
PremisecitationSenescent T cells have defective killing abilities and develop negative regulatory functions.
“In addition to phenotypic alteration, senescent T cells manifest defective killing abilities and the development of negative regulatory functions [52,53].”
Quote in the paperNot a substantial claim0 of 2 sources checked- cites [52] Appay V Nixon DF Donahoe SM Gillespie GM Dong T King A Ogg GS Spiegel HM Conlon C Spina CA HIV-specific CD8(+) T cells produce antiviral cytokines but are impaired in cytolytic function J Exp Med 2000 192 63 75 10880527 PMC1887711 source
Not checked in the free run.
- cites [53] Akbar AN Henson SM Are senescence and exhaustion intertwined or unrelated processes that compromise immunity? Nat Rev Immunol 2011 11 289 295 21436838 source
Not checked in the free run.
May combine two claims.
PremisecitationClinical blockade of B7-H1/PD-1 may rescue T cell effector functions in vivo and results in significant objective clinical responses.
“A promising aspect is that clinical blockade of B7-H1/PD-1, the key T cell exhaustion pathway, may rescue T cell effector functions in vivo, and results in significant objective clinical responses [32,33].”
Quote in the paperSubstantial claim0 of 2 sources checkedMay combine two claims.
PremisecitationHuman HCC-associated T cells highly express Tim-3 and cyclin-dependent kinase inhibitors, interact with galectin-9+ myeloid APCs, and fail to enter the cell cycle.
“human HCC- associated T cells highly express Tim-3 and cyclin dependent kinase inhibitors, and interact with galectin-9+myeloid APCs. These cells fail to enter the cell cycle [40].”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [40] Li H Wu K Tao K Chen L Zheng Q Lu X Liu J Shi L Liu C Wang G Tim-3/galectin-9 signaling pathway mediates T-cell dysfunction and predicts poor prognosis in patients with hepatitis B virus-associated hepatocellular carcinoma Hepatology 2012 56 1342 1351 22505239 source
Not checked in the free run.
Probably not a substantial claim: may not pass S3 (load-bearing).
PremisecitationBat3 modulates Tim-3 function on T cells by interacting with the Tim-3 cytoplasmic tail.
“it has been postulated that the human leukocyte antigen (HLA)-B-associated transcript 3 (Bat3) modulates Tim-3 function on T cells by interacting with Tim-3 cytoplasmic tail [66].”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [66] Rangachari M Zhu C Sakuishi K Xiao S Karman J Chen A Angin M Wakeham A Greenfield EA Sobel RA Bat3 promotes T cell responses and autoimmunity by repressing Tim-3-mediated cell death and exhaustion Nat Med 2012 18 1394 1400 22863785 PMC3491118 source
Not checked in the free run.
May combine two claims.
PremisecitationSenescent T cells are characterized by telomere shortening, loss of CD28 expression, and cell cycle arrest.
“Senescent T cells are characterized by telomere shortenings, phenotypic change (loss of CD28 expression), and cell cycle arrest [46,47] (Fig. 1).”
Quote in the paperNot a substantial claim0 of 2 sources checked- cites [46] Adibzadeh M Pohla H Rehbein A Pawelec G Long-term culture of monoclonal human T lymphocytes: models for immunosenescence? Mech Ageing Dev 1995 83 171 183 8583835 source
Not checked in the free run.
- cites [47] Effros RB Replicative senescence in the immune system: impact of the Hayflick limit on T-cell function in the elderly Am J Hum Genet 1998 62 1003 1007 9545415 PMC1377102 source
Not checked in the free run.
May combine two claims.
PremisecitationSenescent CD28−/dim CD8+ T cells are observed in patients with lung cancer and head and neck cancer.
“Phenotypically, senescent CD28−/dimCD8+T cells are observed in patients with lung cancers [57], head and neck cancer [58].”
Quote in the paperNot a substantial claim0 of 2 sources checked- cites [57] Meloni F Morosini M Solari N Passadore I Nascimbene C Novo M Ferrari M Cosentino M Marino F Pozzi E Foxp3 expressing CD4+ CD25+ and CD8+CD28− T regulatory cells in the peripheral blood of patients with lung cancer and pleural mesothelioma Hum Immunol 2006 67 1 12 16698419 source
Not checked in the free run.
- cites [58] Tsukishiro T Donnenberg AD Whiteside TL Rapid turnover of the CD8(+)CD28(−) T-cell subset of effector cells in the circulation of patients with head and neck cancer Cancer Immunol Immunother 2003 52 599 607 12827303 PMC11032778 source
Not checked in the free run.
May combine two claims.
PremisecitationIn a mouse model, CD44lowCD62Lhigh memory CD8+ T cells express high levels of Sca-1, Bcl-2, and CD122, and because they show robust self-renewal and multipotent capacity to generate central and effector memory T cells, they were designated T memory stem cells.
“In a mouse model, CD44lowCD62Lhigh memory CD8+ T cells express high levels of stem cell antigen-1 (Sca-1), Bcl-2 and common IL-2 and IL-15 receptor β chain (CD122). Because these cells showed robust self-renewal and the multipotent capacity to generate central memory and effector memory T cells, they were designated T memory stem cells [69].”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [69] Zhang Y Joe G Hexner E Zhu J Emerson SG Host-reactive CD8+ memory stem cells in graft-versus-host disease Nat Med 2005 11 1299 1305 16288282 source
Not checked in the free run.
May combine two claims.
InterpretationcitationCells in younger patients may become senescent, and chronic activation and proliferation may cause T cell senescence.
“This suggests that cells in younger patients may become senescent, and chronic activation and proliferation may still cause T cell senescence [55].”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [55] Vallejo AN Weyand CM Goronzy JJ T-cell senescence: a culprit of immune abnormalities in chronic inflammation and persistent infection Trends Mol Med 2004 10 119 124 15102354 source
Not checked in the free run.
May combine two claims.
PremisecitationGalectin-9 induces intracellular calcium flux, aggregation, and death of Th1 cells in a Tim-3-dependent manner.
“Galectin-9 induces intracellular calcium flux, aggregation and death of Th1 cells in Tim-3-dependent manner [65].”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [65] Zhu C Anderson AC Schubart A Xiong H Imitola J Khoury SJ Zheng XX Strom TB Kuchroo VK The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity Nat Immunol 2005 6 1245 1252 16286920 source
Not checked in the free run.
May combine two claims.
InterpretationcitationPD-1 may mark exhausted cells, Tim-3 and KLRG-1 may mark senescent cells, and mouse stem-like T cells may express Sca-1.
“It is arguable but experimentally operative that PD-1 may be a marker for exhausted cells, Tim-3 and KLRG-1 may be markers for senescent cells, and mouse stem-like T cells may express Sca-1 [70].”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [70] Gattinoni L Zhong XS Palmer DC Ji Y Hinrichs CS Yu Z Wrzesinski C Boni A Cassard L Garvin LM Wnt signaling arrests effector T cell differentiation and generates CD8+ memory stem cells Nat Med 2009 15 808 813 19525962 PMC2707501 source
Not checked in the free run.
May combine two claims.
InterpretationreasoningB7-H1/PD-1 and Tim-3/galectin-9 signaling pathways may synergistically and/or additively mediate T cell dysfunction, and simultaneous blockade may improve T cell immunity.
“it is evident that B7-H1/PD-1 and Tim-3/galectin-9 signaling pathways may synergistically and/or additively mediate T cell dysfunction, and simultaneous blockade of these pathways may result in improved T cell immunity.”
Quote in the paperSubstantial claimMay combine two claims.
PremisecitationHuman Th17 cells give rise to distinct Th lineages, as measured by IFNγ and Foxp3+ cell expression, and have heightened self-renewal and survival capabilities.
“Human Th17 cells were shown to give rise to distinct Th lineages, as measured through the expression of IFNγ, and Foxp3+ cells, heightened self-renewal, and survival capabilities [71,72].”
Quote in the paperSubstantial claim0 of 2 sources checkedMay combine two claims.
PremisecitationTh17 cells retain a stem cell-like phenotype through coordinated effects of HIF1α/Notch/Bcl-2 and are potent anti-tumor effectors.
“Interestingly, Th17 cells retain a stem cell-like phenotype through the coordinated effects of HIF1α/Notch/Bcl-2 and are also potent anti-tumor effectors [71], suggesting that stemness might correlate with better immune responses.”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [71] source
Not checked in the free run.
May combine two claims.
InterpretationcitationHuman Th17 cells have stem cell properties at genetic, molecular, and functional levels and are long-lived.
“Human Th17 cells have certain “stem cell properties” at the genetic, molecular and functional levels, and are long-lived cells.”
Quote in the paperSubstantial claimMay combine two claims.
PremisecitationMouse and human Th17 cells display greater survival potential, persistence, and the ability to repopulate sub-lethally irradiated mice.
“When measured for their biological activity, mouse and human Th17 cells displayed greater survival potential, persistence as well as the ability of repopulating sub-lethally irradiated mice [**71,**72].”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [**71,**72]
Not checked in the free run.
The paper relies on this without support.
Human tumors progress despite the presence of tumor-associated antigen-specific T cells.
“Human tumors progress despite the presence of tumor associated antigen (TAA)-specific T cells.”
The paper relies on this without support.
T cell exhaustion occurs when T cells are chronically activated at sites of chronic inflammation, such as cancer, autoimmunity, and chronic infection.
“T cell exhaustion occurs when T cells are chronically activated at sites of chronic inflammation, such as cancer, autoimmunity, and chronic infection.”
The authors state this as an assumption.
The tumor microenvironment provides the necessary conditions for effector T cells to become functionally exhausted and to maintain this state during disease progression.
“Nonetheless, it is assumed that the tumor microenvironment provides the necessary conditions for effector T cells to become functionally exhausted as well as being able to maintain this state during disease progression.”
The paper relies on this without support.
These markers are not mutually exclusive or inclusive in a given T cell subset.
“However, these markers are not mutually exclusive and inclusive in a given T cell subset.”
The paper relies on this without support.
PD-1+ cells may express Tim-3 and LAG-3.
“PD-1+ cells may express Tim-3 and LAG-3.”
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Exhausted T cells are usually CM/EM T cells that have been chronically stimulated.
“Exhausted T cells are usually CM/EM T cells that have been chronically stimulated [341].”
From Guidelines for the use of flow cytometry and cell sorting in immunological studies (third edition) (2021) · cites this paper as [341]
The “T cell exhaustion” section says exhaustion occurs when T cells are chronically activated and describes exhausted cells as effector T cells. It does not say they are usually central-memory or effector-memory (CM/EM) T cells; those memory subsets are discussed separately in “T cell stemness.” Page numbers are unavailable in our copy. (LLM, conf=0.88)
Experimental — accuracy not yet measuredDuring aging, the cytotoxic activity of immune cells decreases, and the expression of functional molecules associated with cytotoxic activity, such as IFN-γ, granzyme B, and perforin, is reduced.
“More recent studies have shown that, during aging, the cytotoxic activity of immune cells decreases, and the expression of functional molecules associated with cytotoxic activity, such as interferon gamma (IFN-γ), granzyme B, and perforin, is also reduced [31–34] (Table 1).”
From Immunosenescence: a key player in cancer development (2020) · cites this paper as [31]
T cell senescence is irreversible, whereas anergy and exhaustion are considered reversible.
“T cell senescence is irreversible, as opposed to their anergy and exhaustion, both of which are considered reversible [31, 38–40].”
From Immunosenescence: a key player in cancer development (2020) · cites this paper as [31]
Cites
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838 · see citing works
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628 · see citing works
The serial cultivation of human diploid cell strains
Hayflick, L., & Moorhead, P. S. (1961) · Experimental Cell Research · doi:10.1016/0014-4827(61)90192-6 · Cited by 8,508 · see citing works
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945 · see citing works
Wherry, E. J. (2011) · Nature Immunology · doi:10.1038/ni.2035 · Cited by 4,062 · see citing works
Restoring function in exhausted CD8 T cells during chronic viral infection
Barber, D. L., Wherry, E. J., Masopust, D., Zhu, B., Allison, J. P., Sharpe, A. H., Freeman, G. J., & Ahmed, R. (2005) · Nature · doi:10.1038/nature04444 · Cited by 3,960 · see citing works
Persistent DNA damage signalling triggers senescence-associated inflammatory cytokine secretion
Rodier, F., Coppé, J.-P., Patil, C. K., Hoeijmakers, W. A. M., Muñoz, D. P., Raza, S. R., Freund, A., Campeau, E., Davalos, A. R., & Campisi, J. (2009) · Nature Cell Biology · doi:10.1038/ncb1909 · Cited by 2,232 · see citing works
Molecular Signature of CD8+ T Cell Exhaustion during Chronic Viral Infection
Wherry, E. J., Ha, S.-J., Kaech, S. M., Haining, W. N., Sarkar, S., Kalia, V., Subramaniam, S., Blattman, J. N., Barber, D. L., & Ahmed, R. (2007) · Immunity · doi:10.1016/j.immuni.2007.09.006 · Cited by 2,103 · see citing works
Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity
Sakuishi, K., Apetoh, L., Sullivan, J. M., Blazar, B. R., Kuchroo, V. K., & Anderson, A. C. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20100643 · Cited by 2,072 · see citing works
Blackburn, S. D., Shin, H., Haining, W. N., Zou, T., Workman, C. J., Polley, A., Betts, M. R., Freeman, G. J., Vignali, D. A. A., & Wherry, E. J. (2009) · Nature Immunology · doi:10.1038/ni.1679 · Cited by 2,062 · see citing works
The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity
Zhu, C., Anderson, A. C., Schubart, A., Xiong, H., Imitola, J., Khoury, S. J., Zheng, X. X., Strom, T. B., & Kuchroo, V. K. (2005) · Nature Immunology · doi:10.1038/ni1271 · Cited by 2,057 · see citing works
Immunosuppressive networks in the tumour environment and their therapeutic relevance
Zou, W. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1586 · Cited by 2,057 · see citing works
Self-citationCalcium oscillations increase the efficiency and specificity of gene expression
Dolmetsch, R. E., Xu, K., & Lewis, R. S. (1998) · Nature · doi:10.1038/31960 · Cited by 1,896 · see citing works
A cell culture model for T lymphocyte clonal anergy
Schwartz, R. H. (1990) · Science · doi:10.1126/science.2113314 · Cited by 1,857 · see citing works
Woo, S.-R., Turnis, M. E., Goldberg, M. V., Bankoti, J., Selby, M., Nirschl, C. J., Bettini, M. L., Gravano, D. M., Vogel, P., Liu, C. L., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-1620 · Cited by 1,647 · see citing works
Inhibitory B7-family molecules in the tumour microenvironment
Zou, W., & Chen, L. (2008) · Nature Reviews Immunology · doi:10.1038/nri2326 · Cited by 1,608 · see citing works
Self-citationCombining immunotherapy and targeted therapies in cancer treatment
Vanneman, M. W., & Dranoff, G. (2012) · Nature reviews. Cancer · doi:10.1038/nrc3237 · Cited by 1,583 · see citing works
Schwartz, R. H. (2003) · Annual Review of Immunology · doi:10.1146/annurev.immunol.21.120601.141110 · Cited by 1,487 · see citing works
Reversal of human cellular senescence: roles of the p53 and p16 pathways
Beauséjour, C. M., Krtolica, A., Galimi, F., Narita, M., Lowe, S. W., Yaswen, P., & Campisi, J. (2003) · The EMBO Journal · doi:10.1093/emboj/cdg417 · Cited by 1,457 · see citing works
Molecular Signature of CD8+ T Cell Exhaustion during Chronic Viral Infection
Wherry, E. J., Ha, S., Kaech, S. M., Haining, W. N., Sarkar, S., Kalia, V., Subramaniam, S., Blattman, J. N., Barber, D. L., & Ahmed, R. (2007) · Immunity · doi:10.1016/j.immuni.2007.11.006 · Cited by 1,355 · see citing works
Role of LAG-3 in Regulatory T Cells
Huang, C.-T., Workman, C. J., Flies, D., Pan, X., Marson, A. L., Zhou, G., Hipkiss, E. L., Ravi, S., Kowalski, J., Levitsky, H. I., et al. (2004) · Immunity · doi:10.1016/j.immuni.2004.08.010 · Cited by 1,325 · see citing works
Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity
Curiel, T. J., Wei, S., Dong, H., Alvarez, X., Cheng, P., Mottram, P., Krzysiek, R., Knutson, K. L., Daniel, B., Zimmermann, M. C., et al. (2003) · Nature Medicine · doi:10.1038/nm863 · Cited by 1,314 · see citing works
Self-citationFourcade, J., Sun, Z., Benallaoua, M., Guillaume, P., Luescher, I. F., Sander, C., Kirkwood, J. M., Kuchroo, V., & Zarour, H. M. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20100637 · Cited by 1,307 · see citing works
Brenchley, J. M., Karandikar, N. J., Betts, M. R., Ambrozak, D. R., Hill, B. J., Crotty, L. E., Casazza, J. P., Kuruppu, J., Migueles, S. A., Connors, M., et al. (2003) · Blood · doi:10.1182/blood-2002-07-2103 · Cited by 1,073 · see citing works
Chen, L., Ashe, S., Brady, W. A., Hellström, I., Hellström, K. E., Ledbetter, J. A., McGowan, P., & Linsley, P. S. (1992) · Cell · doi:10.1016/s0092-8674(05)80059-5 · Cited by 1,050 · see citing works
Wnt signaling arrests effector T cell differentiation and generates CD8+ memory stem cells
Gattinoni, L., Zhong, X.-S., Palmer, D. C., Ji, Y., Hinrichs, C. S., Yu, Z., Wrzesinski, C., Boni, A., Cassard, L., Garvin, L. M., et al. (2009) · Nature Medicine · doi:10.1038/nm.1982 · Cited by 1,031 · see citing works
Feedback between p21 and reactive oxygen production is necessary for cell senescence
Passos, J. F., Nelson, G., Wang, C., Richter, T., Simillion, C., Proctor, C. J., Miwa, S., Olijslagers, S., Hallinan, J., Wipat, A., et al. (2010) · Molecular Systems Biology · doi:10.1038/msb.2010.5 · Cited by 1,019 · see citing works
HIV-specific CD8(+) T cells produce antiviral cytokines but are impaired in cytolytic function
Appay, V., Nixon, D. F., Donahoe, S. M., Gillespie, G. M. A., Dong, T., King, A., Ogg, G. S., Spiegel, H. M. L., Conlon, C., Spina, C. A., et al. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.1.63 · Cited by 871 · see citing works
Cooperation of Tim-3 and PD-1 in CD8 T-cell exhaustion during chronic viral infection
Jin, H.-T., Anderson, A. C., Tan, W. G., West, E. E., Ha, S.-J., Araki, K., Freeman, G. J., Kuchroo, V. K., & Ahmed, R. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1009731107 · Cited by 858 · see citing works
Exhaustion of tumor-specific CD8+ T cells in metastases from melanoma patients
Baitsch, L., Baumgaertner, P., Devêvre, E., Raghav, S. K., Legat, A., Barba, L., Wieckowski, S., Bouzourene, H., Deplancke, B., Romero, P., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci46102 · Cited by 845 · see citing works
PD-1 signaling in primary T cells
Riley, J. L. (2009) · Immunological Reviews · doi:10.1111/j.1600-065x.2009.00767.x · Cited by 778 · see citing works
Blank, C., Brown, I., Peterson, A. C., Spiotto, M., Iwai, Y., Honjo, T., & Gajewski, T. F. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3259 · Cited by 772 · see citing works
B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma
Kryczek, I., Zou, L., Rodriguez, P., Zhu, G., Wei, S., Mottram, P., Brumlik, M., Cheng, P., Curiel, T., Myers, L., et al. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20050930 · Cited by 748 · see citing works
Self-citationZhou, Q., Munger, M. E., Veenstra, R. G., Weigel, B. J., Hirashima, M., Munn, D. H., Murphy, W. J., Azuma, M., Anderson, A. C., Kuchroo, V. K., et al. (2011) · Blood · doi:10.1182/blood-2010-10-310425 · Cited by 675 · see citing works
Li, H., Wu, K., Tao, K., Chen, L., Zheng, Q., Lu, X., Liu, J., Shi, L., Liu, C., Wang, G., et al. (2012) · Hepatology · doi:10.1002/hep.25777 · Cited by 496 · see citing works
Self-citationProgressive differentiation and selection of the fittest in the immune response
Lanzavecchia, A., & Sallusto, F. (2002) · Nature Reviews Immunology · doi:10.1038/nri959 · Cited by 495 · see citing works
Are senescence and exhaustion intertwined or unrelated processes that compromise immunity?
Akbar, A. N., & Henson, S. M. (2011) · Nature Reviews Immunology · doi:10.1038/nri2959 · Cited by 474 · cited 1× · see citing works
“In addition to phenotypic alteration, senescent T cells manifest defective killing abilities and the development of negative regulatory functions [52,53].”
BackgroundTh17 cells are long lived and retain a stem cell-like molecular signature
Muranski, P., Borman, Z. A., Kerkar, S. P., Klebanoff, C. A., Ji, Y., Sanchez-Perez, L., Sukumar, M., Reger, R. N., Yu, Z., Kern, S. J., et al. (2011) · Immunity · doi:10.1016/j.immuni.2011.09.019 · Cited by 443 · see citing works
CTLA-4 regulates induction of anergy in vivo
Greenwald, R. J., Boussiotis, V. A., Lorsbach, R. B., Abbas, A. K., & Sharpe, A. H. (2001) · Immunity · doi:10.1016/s1074-7613(01)00097-8 · Cited by 428 · see citing works
Maintenance of Human T Cell Anergy: Blocking of IL-2 Gene Transcription by Activated Rap1
Boussiotis, V. A., Freeman, G. J., Berezovskaya, A., Barber, D. L., & Nadler, L. M. (1997) · Science · doi:10.1126/science.278.5335.124 · Cited by 408 · see citing works
Rangachari, M., Zhu, C., Sakuishi, K., Xiao, S., Karman, J., Chen, A., Angin, M., Wakeham, A., Greenfield, E. A., Sobel, R. A., et al. (2012) · Nature Medicine · doi:10.1038/nm.2871 · Cited by 394 · see citing works
Wu, K., Kryczek, I., Chen, L., Zou, W., & Welling, T. H. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-0901 · Cited by 380 · see citing works
Self-citationBengsch, B., Seigel, B., Ruhl, M., Timm, J., Kuntz, M., Blum, H. E., Pircher, H., & Thimme, R. (2010) · PLoS Pathogens · doi:10.1371/journal.ppat.1000947 · Cited by 373 · see citing works
Fourcade, J., Sun, Z., Pagliano, O., Guillaume, P., Luescher, I. F., Sander, C., Kirkwood, J. M., Olive, D., Kuchroo, V., & Zarour, H. M. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-2637 · Cited by 372 · see citing works
Host-reactive CD8+ memory stem cells in graft-versus-host disease
Zhang, Y., Joe, G., Hexner, E., Zhu, J., & Emerson, S. G. (2005) · Nature Medicine · doi:10.1038/nm1326 · Cited by 369 · see citing works
Workman, C. J., Cauley, L. S., Kim, I.-J., Blackman, M. A., Woodland, D. L., & Vignali, D. A. A. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.9.5450 · Cited by 351 · see citing works
Essential role of the E3 ubiquitin ligase Cbl-b in T cell anergy induction
Jeon, M.-S., Atfield, A., Venuprasad, K., Krawczyk, C., Sarao, R., Elly, C., Yang, C., Arya, S., Bachmaier, K., Su, L., et al. (2004) · Immunity · doi:10.1016/j.immuni.2004.07.013 · Cited by 348 · see citing works
Blockade of PD‐L1 (B7‐H1) augments human tumor‐specific T cell responses <i>in vitro</i>
Blank, C., Kuball, J., Voelkl, S., Wiendl, H., Becker, B., Walter, B., Majdic, O., Gajewski, T. F., Theobald, M., Andreesen, R., et al. (2006) · International Journal of Cancer · doi:10.1002/ijc.21775 · Cited by 297 · see citing works
Derré, L., Rivals, J.-P., Jandus, C., Pastor, S., Rimoldi, D., Romero, P., Michielin, O., Olive, D., & Speiser, D. E. (2010) · Journal of Clinical Investigation · doi:10.1172/jci40070 · Cited by 295 · see citing works
Anandasabapathy (2003) · doi:10.1016/s1074-7613(03)00084-0 · Cited by 285 · see citing works
Human T <sub>H</sub> 17 Cells Are Long-Lived Effector Memory Cells
Kryczek, I., Zhao, E., Liu, Y., Wang, Y., Vatan, L., Szeliga, W., Moyer, J., Klimczak, A., Lange, A., & Zou, W. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002949 · Cited by 278 · see citing works
Self-citationArrested differentiation, the self-renewing memory lymphocyte, and vaccination
Fearon, D. T., Manders, P., & Wagner, S. D. (2001) · Science · doi:10.1126/science.1062589 · Cited by 265 · see citing works
Nazareth, M. R., Broderick, L., Simpson-Abelson, M. R., Kelleher, R. J., Yokota, S. J., & Bankert, R. B. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.9.5552 · Cited by 259 · see citing works
Viral infections induce abundant numbers of senescent CD8 T cells
Voehringer, D., Blaser, C., Brawand, P., Raulet, D. H., Hanke, T., & Pircher, H. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.167.9.4838 · Cited by 246 · see citing works
E3 ubiquitin ligases as T cell anergy factors
Mueller, D. L. (2004) · Nature Immunology · doi:10.1038/ni1106 · Cited by 224 · cited 1× · see citing works
“The E3 ubiquiting ligase family can affect PI3K, mTOR, and Ras/MAPK signaling pathways and help to actively maintain anergy [21,23,24].”
BackgroundVallejo, A. N., Weyand, C. M., & Goronzy, J. J. (2004) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2004.01.002 · Cited by 223 · see citing works
Role of PD-1 and its ligand, B7-H1, in early fate decisions of CD8 T cells
Goldberg, M. V., Maris, C. H., Hipkiss, E. L., Flies, A. S., Zhen, L., Tuder, R. M., Grosso, J. F., Harris, T., Getnet, D., Whartenby, K. A., et al. (2007) · Blood · doi:10.1182/blood-2006-12-062422 · Cited by 187 · see citing works
Meloni, F., Morosini, M., Solari, N., Passadore, I., Nascimbene, C., Novo, M., Ferrari, M., Cosentino, M., Marino, F., Pozzi, E., et al. (2006) · Human Immunology · doi:10.1016/j.humimm.2005.11.005 · Cited by 169 · see citing works
Tsukishiro, T., Donnenberg, A. D., & Whiteside, T. L. (2003) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-003-0395-6 · Cited by 158 · see citing works
Huang, X., Bai, X., Cao, Y., Wu, J., Huang, M., Tang, D., Tao, S., Zhu, T., Liu, Y., Yang, Y., et al. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20090397 · Cited by 156 · see citing works
Wells, A. D. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0803917 · Cited by 153 · see citing works
Tumor-induced senescent T cells with suppressor function: a potential form of tumor immune evasion
Montes, C. L., Chapoval, A. I., Nelson, J., Orhue, V., Zhang, X., Schulze, D. H., Strome, S. E., & Gastman, B. R. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-2282 · Cited by 127 · see citing works
B7-1 but not B7-2 efficiently costimulates CD8+ T lymphocytes in the P815 tumor system in vitro
Gajewski, T. F. (1996) · The Journal of Immunology · doi:10.4049/jimmunol.156.2.465 · Cited by 114 · see citing works
Zheng, Y., Zha, Y., Driessens, G., Locke, F. L., & Gajewski, T. F. (2012) · The Journal of Experimental Medicine · doi:10.1084/jem.20120342 · Cited by 106 · see citing works
Effros, R. B. (1998) · The American Journal of Human Genetics · doi:10.1086/301845 · Cited by 105 · see citing works
Bandyopadhyay, S., Duré, M., Paroder, M., Soto-Nieves, N., Puga, I., & Macián, F. (2007) · Blood · doi:10.1182/blood-2006-07-037754 · Cited by 104 · see citing works
Gao, B., Kong, Q., Kemp, K., Zhao, Y.-S., & Fang, D. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1118462109 · Cited by 98 · see citing works
Heffner, M., & Fearon, D. T. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0706040104 · Cited by 92 · see citing works
Thomas, R. M., Chunder, N., Chen, C., Umetsu, S. E., Winandy, S., & Wells, A. D. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.11.7305 · Cited by 91 · see citing works
Brown, I. E., Blank, C., Kline, J., Kacha, A. K., & Gajewski, T. F. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.7.4521 · Cited by 91 · see citing works
Transcriptional complexes formed by NFAT dimers regulate the induction of T cell tolerance
Soto-Nieves, N., Puga, I., Abe, B. T., Bandyopadhyay, S., Baine, I., Rao, A., & Macian, F. (2009) · Journal of Experimental Medicine · doi:10.1084/jem.20082731 · Cited by 86 · see citing works
PD-1 and BTLA and CD8+T-cell “exhaustion” in cancer
Haymaker, C., Wu, R. C. H., Bernatchez, C., & Radvanyi, L. G. (2012) · OncoImmunology · doi:10.4161/onci.20823 · Cited by 83 · see citing works
DNA damage-induced cellular senescence is sufficient to suppress tumorigenesis: a mouse model
Van Nguyen, T., Puebla-Osorio, N., Pang, H., Dujka, M. E., & Zhu, C. (2007) · The Journal of Experimental Medicine · doi:10.1084/jem.20062453 · Cited by 72 · see citing works
Long-term culture of monoclonal human T lymphocytes: models for immunosenescence?
Adibzadeh, M., Pohla, H., Rehbein, A., & Pawelec, G. (1995) · Mechanisms of Ageing and Development · doi:10.1016/0047-6374(95)01625-a · Cited by 64 · see citing works
Th17 cells have stem cell-like features and promote long-term immunity
Wei, S., Zhao, E., Kryczek, I., & Zou, W. (2012) · OncoImmunology · doi:10.4161/onci.19440 · Cited by 49 · see citing works
Self-citationIL-12 reverses anergy to T cell receptor triggering in human lung tumor-associated memory T cells
Broderick, L., Brooks, S. P., Takita, H., Baer, A. N., Bernstein, J. M., & Bankert, R. B. (2006) · Clinical Immunology · doi:10.1016/j.clim.2005.09.008 · Cited by 47 · see citing works
Immunoageing—the cause or effect of morbidity
Pawelec, G., & Solana, R. (2001) · Trends in Immunology · doi:10.1016/s1471-4906(01)01956-1 · Cited by 29 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression
Chang, C.-H., Qiu, J., O’Sullivan, D., Buck, M. D., Noguchi, T., Curtis, J. D., Chen, Q., Gindin, M., Gubin, M. M., van der Windt, G. J. W., et al. (2015) · Cell · doi:10.1016/j.cell.2015.08.016 · Cited by 3,331 · see citing works
Inflammation and tumor progression: signaling pathways and targeted intervention
Zhao, H., Wu, L., Yan, G., Chen, Y., Zhou, M., Wu, Y., & Li, Y. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00658-5 · Cited by 2,907 · see citing works
Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy
Nagarsheth, N., Wicha, M. S., & Zou, W. (2017) · Nature reviews. Immunology · doi:10.1038/nri.2017.49 · Cited by 2,196 · see citing works
Self-citationSenescence in Health and Disease
He, S., & Sharpless, N. E. (2017) · Cell · doi:10.1016/j.cell.2017.05.015 · Cited by 1,766 · see citing works
Saxena, M., van der Burg, S. H., Melief, C. J. M., & Bhardwaj, N. (2021) · Nature reviews. Cancer · doi:10.1038/s41568-021-00346-0 · Cited by 1,581 · see citing works
Schirrmacher, V. (2018) · International Journal of Oncology · doi:10.3892/ijo.2018.4661 · Cited by 1,303 · see citing works
Cellular Senescence: Aging, Cancer, and Injury
Calcinotto, A., Kohli, J., Zagato, E., Pellegrini, L., Demaria, M., & Alimonti, A. (2019) · Physiological Reviews · doi:10.1152/physrev.00020.2018 · Cited by 1,270 · see citing works
The Immunoreceptor TIGIT Regulates Antitumor and Antiviral CD8 + T Cell Effector Function
Johnston, R. J., Comps‐Agrar, L., Hackney, J. A., Yu, X., Huseni, M. A., Yang, Y., Park, S., Javinal, V., Chiu, H. H., Irving, B. A., et al. (2014) · Cancer Cell · doi:10.1016/j.ccell.2014.10.018 · Cited by 1,191 · see citing works
Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing
Yadav, M., Jhunjhunwala, S., Phung, Q. T., Lupardus, P., Tanguay, J., Bumbaca, S., Franci, C., Cheung, T. K., Fritsche, J., Weinschenk, T., et al. (2014) · Nature · doi:10.1038/nature14001 · Cited by 1,186 · see citing works
Melief, C. J. M., van Hall, T., Arens, R., OSSENDORP, F. A., & van der Burg, S. H. (2015) · Journal of Clinical Investigation · doi:10.1172/jci80009 · Cited by 1,182 · see citing works
The Principles of Engineering Immune Cells to Treat Cancer
Lim, W. A., & June, C. H. (2017) · Cell · doi:10.1016/j.cell.2017.01.016 · Cited by 1,084 · see citing works
Immunosenescence: molecular mechanisms and diseases
Liu, Z., Liang, Q., Ren, Y., Guo, C., Ge, X., Wang, L., Cheng, Q., Luo, P., Zhang, Y., & Han, X. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01451-2 · Cited by 1,023 · see citing works
Tumorigenic and Immunosuppressive Effects of Endoplasmic Reticulum Stress in Cancer
Cubillos-Ruiz, J., Bettigole, S., & Glimcher, L. (2017) · Cell · doi:10.1016/j.cell.2016.12.004 · Cited by 815 · see citing works
Wang, Z., Aguilar, E. G., Luna, J. I., Dunai, C., Khuat, L. T., Le, C. T., Mirsoian, A., Minnar, C. M., Stoffel, K. M., Sturgill, I. R., et al. (2019) · Nature Medicine · doi:10.1038/s41591-018-0221-5 · Cited by 865 · see citing works
Scharping, N. E., Menk, A. V., Moreci, R. S., Whetstone, R. D., Dadey, R. E., Watkins, S. C., Ferris, R. L., & Delgoffe, G. M. (2016) · Immunity · doi:10.1016/j.immuni.2016.07.009 · Cited by 848 · see citing works
Synthetic Nanoparticles for Vaccines and Immunotherapy
Irvine, D. J., Hanson, M. C., Rakhra, K., & Tokatlian, T. (2015) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00109 · Cited by 770 · see citing works
Schietinger, A., Philip, M., Krisnawan, V. E., Chiu, E. Y., Delrow, J. J., Basom, R. S., Lauer, P., Brockstedt, D. G., Knoblaugh, S. E., Hämmerling, G. J., et al. (2016) · Immunity · doi:10.1016/j.immuni.2016.07.011 · Cited by 720 · see citing works
Scharping, N. E., Menk, A. V., Moreci, R. S., Whetstone, R. D., Dadey, R., Watkins, S. C., Ferris, R. L., & Delgoffe, G. M. (2016) · Immunity · doi:10.1016/j.immuni.2016.08.009 · Cited by 705 · see citing works
Circulating and disseminated tumour cells — mechanisms of immune surveillance and escape
Mohme, M., Riethdorf, S., & Pantel, K. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.144 · Cited by 603 · see citing works
Peng, Q., Qiu, X., Zhang, Z., Zhang, S., Zhang, Y., Liang, Y., Guo, J., Peng, H., Chen, M., Fu, Y.-X., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-18570-x · Cited by 553 · see citing works
Liu, X., Ranganathan, R., Jiang, S., Fang, C., Sun, J., Kim, S., Newick, K., Lo, A., June, C. H., Zhao, Y., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-2524 · Cited by 524 · see citing works
Guidelines for the use of flow cytometry and cell sorting in immunological studies (third edition)
Cossarizza, A., Chang, H., Radbruch, A., Abrignani, S., Addo, R., Akdis, M., Andrä, I., Andreata, F., Annunziato, F., Arranz, E., et al. (2021) · European Journal of Immunology · doi:10.1002/eji.202170126 · Cited by 531 · see citing works
Angelova, M., Charoentong, P., Hackl, H., Fischer, M. L., Snajder, R., Krogsdam, A., Waldner, M. J., Bindea, G., Mlecnik, B., Galon, J., et al. (2015) · Genome biology · doi:10.1186/s13059-015-0620-6 · Cited by 521 · see citing works
Immunosenescence: a key player in cancer development
Lian, J., Yue, Y., Yu, W., & Zhang, Y. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00986-z · Cited by 510 · see citing works
Facilitating T Cell Infiltration in Tumor Microenvironment Overcomes Resistance to PD-L1 Blockade
Tang, H., Wang, Y., Chlewicki, L. K., Zhang, Y., Guo, J., Liang, W. P., Wang, J., Wang, X., & Fu, Y. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.02.004 · Cited by 477 · see citing works
Fates of CD8+ T cells in Tumor Microenvironment
Maimela, N. R., Liu, S., & Zhang, Y. (2019) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2018.11.004 · Cited by 459 · see citing works
Colorectal Cancer Immunotherapy: Options and Strategies
Johdi, N. A., & SUKOR, N. F. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01624 · Cited by 457 · see citing works
Contributions of Age-Related Thymic Involution to Immunosenescence and Inflammaging
Thomas, R., Wang, W., & Su, D.-M. (2020) · Immunity & Ageing · doi:10.1186/s12979-020-0173-8 · Cited by 442 · see citing works
New insights into the role of <scp>EMT</scp> in tumor immune escape
Terry, S., Savagner, P., Ortiz‐Cuaran, S., Mahjoubi, L., Saintigny, P., Thiery, J., & Chouaib, S. (2017) · Molecular Oncology · doi:10.1002/1878-0261.12093 · Cited by 414 · see citing works
Engineered T Cell Therapy for Cancer in the Clinic
Zhao, L., & Cao, Y. J. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02250 · Cited by 414 · see citing works
CD39 Expression Defines Cell Exhaustion in Tumor-Infiltrating CD8+ T Cells
Canale, F. P., Ramello, M. C., Núñez, N. G., Furlan, C. L. A., Bossio, S., Serrán, M. G., Tosello, J., del Castillo, A., Ledesma, M., Sedlik, C., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-2684 · Cited by 401 · see citing works
Zhao, E., Maj, T., Kryczek, I., Li, W., Wu, K., Zhao, L., Wei, S., Crespo, J., Wan, S., Vatan, L., et al. (2016) · Nature Immunology · doi:10.1038/ni.3313 · Cited by 405 · see citing works
Self-citationMoon, E. K., Wang, L.-C., Dolfi, D. V., Wilson, C. B., Ranganathan, R., Sun, J., Kapoor, V., Scholler, J., Puré, E., Milone, M. C., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2627 · Cited by 405 · see citing works
CAR-T Cell Therapy in Hematological Malignancies: Current Opportunities and Challenges
Zhang, X., Zhu, L., Zhang, H., Chen, S., & Xiao, Y. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.927153 · Cited by 416 · see citing works
Thommen, D. S., Schreiner, J., Müller, P., Herzig, P., Roller, A., Belousov, A., Umaña, P., Pisa, P., Klein, C., Bacac, M., et al. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0097 · Cited by 395 · see citing works
Emerging Cellular Therapies for Cancer
Guedan, S., Ruella, M., & June, C. H. (2018) · Annual Review of Immunology · doi:10.1146/annurev-immunol-042718-041407 · Cited by 386 · see citing works
Ross-Adams, H., Ball, S., Lawrenson, K., Halim, S., Russell, R., Wells, C. A., Strand, S., Orntoft, T., Larson, M., Armasu, S., et al. (2016) · Oncotarget · doi:10.18632/oncotarget · Cited by 392 · see citing works
Exhaustion and senescence: two crucial dysfunctional states of T cells in the tumor microenvironment
Zhao, Y., Shao, Q., & Peng, G. (2020) · Cellular & Molecular Immunology · doi:10.1038/s41423-019-0344-8 · Cited by 382 · see citing works
Xiao, X., Lao, X.-M., Chen, M.-M., Liu, R.-X., Wei, Y., Ouyang, F.-Z., Chen, D.-P., Zhao, X.-Y., Zhao, Q., Li, X.-F., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-1408 · Cited by 352 · see citing works
Exhausted CD8+T Cells in the Tumor Immune Microenvironment: New Pathways to Therapy
Jiang, W., He, Y., He, W., Wu, G. S., Zhou, X., Sheng, Q., Zhong, W., Lu, Y., Ding, Y., Qi, L., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.622509 · Cited by 340 · see citing works
Dynamic Changes in Chromatin Accessibility Occur in CD8 + T Cells Responding to Viral Infection
Scott-Browne, J. P., López-Moyado, I. F., Trifari, S., Wong, V., Chávez, L., Rao, A., & Pereira, R. M. (2016) · Immunity · doi:10.1016/j.immuni.2016.10.028 · Cited by 309 · see citing works
Immunity, Hypoxia, and Metabolism–the Ménage à Trois of Cancer: Implications for Immunotherapy
Riera-Domingo, C., Audigé, A., Granja, S., Cheng, W.-C., Ho, P.-C., Baltazar, F., Stockmann, C., & Mazzone, M. (2020) · Physiological Reviews · doi:10.1152/physrev.00018.2019 · Cited by 310 · see citing works
Immunotherapy and tumor microenvironment
Tang, H., Qiao, J., & Fu, Y. (2015) · Cancer Letters · doi:10.1016/j.canlet.2015.10.009 · Cited by 306 · see citing works
Tim-3: An Emerging Target in the Cancer Immunotherapy Landscape
Anderson, A. C. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0039 · Cited by 302 · see citing works
T cell differentiation in chronic infection and cancer: functional adaptation or exhaustion?
Speiser, D. E., Utzschneider, D. T., Oberle, S. G., Münz, C., Romero, P. J., & Zehn, D. (2014) · Nature reviews. Immunology · doi:10.1038/nri3740 · Cited by 297 · see citing works
Markers of T Cell Senescence in Humans
Xu, W., & Larbi, A. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18081742 · Cited by 261 · see citing works
Immune system and melanoma biology: a balance between immunosurveillance and immune escape
Passarelli, A. M., Mannavola, F., Stucci, L. S., Tucci, M., & Silvestris, F. (2017) · Oncotarget · doi:10.18632/oncotarget.22190 · Cited by 271 · see citing works
T cell senescence and CAR-T cell exhaustion in hematological malignancies
Kasakovski, D., Xu, L., & Li, Y. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0629-x · Cited by 274 · see citing works
PD1 signal transduction pathways in T cells
Arasanz, H., Gato, M., Zuazo, M., Ibáñez-Vea, M., Breckpot, K., Kochan, G. T., & Escors, D. (2017) · Oncotarget · doi:10.18632/oncotarget.17232 · Cited by 273 · see citing works
Peña-Romero, A. C., & Orenes‐Piñero, E. (2022) · Cancers · doi:10.3390/cancers14071681 · Cited by 262 · see citing works
The Immune System in Cancer Pathogenesis: Potential Therapeutic Approaches
Pandya, P. H., Murray, M. E., Pollok, K. E., & Renbarger, J. L. (2016) · Journal of Immunology Research · doi:10.1155/2016/4273943 · Cited by 260 · see citing works
Effector, Memory, and Dysfunctional CD8+T Cell Fates in the Antitumor Immune Response
Reiser, J., & Banerjee, A. (2016) · Journal of Immunology Research · doi:10.1155/2016/8941260 · Cited by 256 · see citing works
Wing, A., Fajardo, C. A., Posey, A. D., Shaw, C. E., Da, T., Young, R. M., Alemany, R., June, C. H., & Guedan, S. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0314 · Cited by 253 · see citing works
Partial exhaustion of CD8 T cells and clinical response to teplizumab in new-onset type 1 diabetes
Long, S. A., Thorpe, J., DeBerg, H. A., Gersuk, V., Eddy, J. A., Harris, K. M., Ehlers, M., Herold, K. C., Nepom, G. T., & Linsley, P. S. (2016) · Science Immunology · doi:10.1126/sciimmunol.aai7793 · Cited by 250 · see citing works
Targeting memory T cell metabolism to improve immunity
Corrado, M., & Pearce, E. L. (2022) · Journal of Clinical Investigation · doi:10.1172/jci148546 · Cited by 234 · see citing works
OX40 Agonists and Combination Immunotherapy: Putting the Pedal to the Metal
Linch, S. N., McNamara, M. J., & Redmond, W. L. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2015.00034 · Cited by 238 · see citing works
NF-kappaB: Two Sides of the Same Coin
Pires, B. R. B., Silva, R. C. M. C., Ferreira, G. M., & Abdelhay, E. S. F. W. (2018) · Genes · doi:10.3390/genes9010024 · Cited by 235 · see citing works
Immune system targeting by biodegradable nanoparticles for cancer vaccines
Silva, J. M., Videira, M., Gaspar, R. S., Véronique Préat, A., & Florindo, H. F. (2013) · Journal of Controlled Release · doi:10.1016/j.jconrel.2013.03.010 · Cited by 232 · see citing works
The Role of Natural Killer T Cells in Cancer—A Phenotypical and Functional Approach
Krijgsman, D., Hokland, M., & Kuppen, P. J. K. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00367 · Cited by 230 · see citing works
Regulatory T cells trigger effector T cell DNA damage and senescence caused by metabolic competition
Liu, X., Mo, W., Ye, J., Li, L., Zhang, Y., Hsueh, E. C., Hoft, D. F., & Peng, G. (2018) · Nature Communications · doi:10.1038/s41467-017-02689-5 · Cited by 224 · see citing works
Metabolic Cooperation and Competition in the Tumor Microenvironment: Implications for Therapy
Gupta, S., Roy, A., & Dwarakanath, B. S. R. (2017) · Frontiers in Oncology · doi:10.3389/fonc.2017.00068 · Cited by 218 · see citing works
The Evolving Role of CD8+CD28− Immunosenescent T Cells in Cancer Immunology
Huff, W. X., Kwon, J. H., Henriquez, M., Fetcko, K., & Dey, M. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20112810 · Cited by 217 · see citing works
Knaus, H. A., Berglund, S., Hackl, H., Blackford, A. L., Zeidner, J. F., Montiel-Esparza, R., Mukhopadhyay, R., Vanura, K., Blazar, B. R., Karp, J. E., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.120974 · Cited by 216 · see citing works
Immunotherapy of multiple myeloma
Minnie, S. A., & Hill, G. R. (2020) · Journal of Clinical Investigation · doi:10.1172/jci129205 · Cited by 216 · see citing works
Stem Cell Plasticity and Dormancy in the Development of Cancer Therapy Resistance
Angelis, M. L. D., Francescangeli, F., Torre, F. L., & Zeuner, A. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00626 · Cited by 203 · see citing works
Hydrogel dual delivered celecoxib and anti-PD-1 synergistically improve antitumor immunity
Li, Y., Fang, M., Zhang, J., Wang, J., Song, Y., Shi, J., Li, W., Wu, G., Ren, J., Wang, Z., et al. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1074374 · Cited by 205 · see citing works
Self-citationSuen, H., Brown, R. D., Yang, S. S., Weatherburn, C., Ho, P. J., Woodland, N., Nassif, N. T., Barbaro, P., Bryant, C. E., Hart, D. N. J., et al. (2016) · Leukemia · doi:10.1038/leu.2016.84 · Cited by 201 · see citing works
T cell exhaustion: from pathophysiological basics to tumor immunotherapy
Catakovic, K., Klieser, E., Neureiter, D., & Geisberger, R. (2017) · Cell Communication and Signaling · doi:10.1186/s12964-016-0160-z · Cited by 202 · see citing works
The untold story of IFN-γ in cancer biology
Kursunel, M. A., & Esendagli, G. (2016) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2016.07.005 · Cited by 192 · see citing works
Westendorf, A. M., Skibbe, K., Adamczyk, A., Buer, J., Geffers, R., Hansen, W., Pastille, E., & Jendrossek, V. (2017) · Cellular Physiology and Biochemistry · doi:10.1159/000464429 · Cited by 189 · see citing works
Ørskov, A. D., Treppendahl, M. B., Skovbo, A., Holm, M. S., Friis, L. S., Hokland, M., & Grønbæk, K. (2015) · Oncotarget · doi:10.18632/oncotarget.3324 · Cited by 188 · see citing works
Tumor Microenvironment: A Metabolic Player that Shapes the Immune Response
Cassim, S., & Pouysségur, J. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms21010157 · Cited by 189 · see citing works
Chemokine-Directed Tumor Microenvironment Modulation in Cancer Immunotherapy
Bule, P., Aguiar, S. I., Aires‐da‐Silva, F., & Dias, J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22189804 · Cited by 187 · see citing works
Bispecific and multispecific antibodies in oncology: opportunities and challenges
Goebeler, M.-E., Stuhler, G., & Bargou, R. C. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-024-00905-y · Cited by 191 · see citing works
Kabacaoğlu, D., Ciecielski, K. J., Ruess, D. A., & Algül, H. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01878 · Cited by 175 · see citing works
Ikeda, S., Okamoto, T., Okano, S., Umemoto, Y., Tagawa, T., Morodomi, Y., Kohno, M., Shimamatsu, S., Kitahara, H., Suzuki, Y., et al. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2015.09.010 · Cited by 179 · see citing works
Host Immune Response to Infection and Cancer: Unexpected Commonalities
Goldszmid, R. S., Dzutsev, A., & Trinchieri, G. (2014) · Cell Host & Microbe · doi:10.1016/j.chom.2014.02.003 · Cited by 165 · see citing works
Cao, Y., Trillo-Tinoco, J., Sierra, R. A., Anadon, C., Dai, W., Mohamed, E., Cen, L., Costich, T. L., Magliocco, A., Marchion, D., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-09263-1 · Cited by 161 · see citing works
Saeed, M., Gao, J. X., Shi, Y., Lammers, T., & Yu, H. (2019) · Theranostics · doi:10.7150/thno.37568 · Cited by 155 · see citing works
Gemta, L. F., Siska, P. J., Nelson, M. E., Gao, X., Liu, X., Locasale, J. W., Yagita∥, H., Slingluff, C. L., Hoehn, K. L., Rathmell, J. C., et al. (2019) · Science Immunology · doi:10.1126/sciimmunol.aap9520 · Cited by 155 · see citing works
Mohme, M., Schliffke, S., Maire, C. L., Rünger, A., Glau, L., Mende, K. C., Matschke, J., Gehbauer, C., Akyüz, N., Zapf, S., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2617 · Cited by 152 · see citing works
Immunosenescence and inflammaging: Mechanisms and role in diseases
Ajoolabady, A., Praticò, D., Tang, D., Zhou, S., Franceschi, C., & Ren, J. T. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102540 · Cited by 160 · see citing works
Cellular senescence impact on immune cell fate and function
Vicente, R., Mausset-Bonnefont, A.-L., Jorgensen, C., Louis-Plence, P., & Brondello, J.-M. (2016) · Aging Cell · doi:10.1111/acel.12455 · Cited by 151 · see citing works
Xia, H., Wang, W., Crespo, J., Kryczek, I., Li, W., Wei, S., Bian, Z., Maj, T., He, M., Liu, J. R., et al. (2017) · Science Immunology · doi:10.1126/sciimmunol.aan4631 · Cited by 155 · see citing works
Self-citationZakharov, P. N., Hu, H., Wan, X., & Unanue, E. R. (2020) · Journal of Experimental Medicine · doi:10.1084/jem.20192362 · Cited by 149 · see citing works
Immunosenescence: signaling pathways, diseases and therapeutic targets
Fu, Y., Wang, B., Alu, A., Hong, W., Hong, L., He, X., Shi, H., Cheng, P., & Yang, X. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02371-z · Cited by 157 · see citing works
Gross, G., & Eshhar, Z. (2016) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010814-124844 · Cited by 147 · see citing works
Lu, Y., Hong, B., Li, H., Zheng, Y., Zhang, M., Wang, S., Qian, J., & Yi, Q. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1317431111 · Cited by 146 · see citing works
T helper 17 (Th17) cells and interleukin-17 (IL-17) in cancer
Chang, S. H. (2019) · Archives of Pharmacal Research · doi:10.1007/s12272-019-01146-9 · Cited by 146 · see citing works
Pateras, I. S., Havaki, S., Nikitopoulou, X., Vougas, K. N., Townsend, P. A., Panayiotidis, M. I., Georgakilas, A. G., & Gorgoulis, V. G. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2015.06.011 · Cited by 143 · see citing works
Recent advances and applications of CRISPR-Cas9 in cancer immunotherapy
Liu, Z., Shi, M., Ren, Y., Xu, H., Weng, S., Ning, W., Ge, X., Liu, L., Guo, C., Duo, M., et al. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01738-6 · Cited by 146 · see citing works
Single-Cell Lymphocyte Heterogeneity in Advanced Cutaneous T-cell Lymphoma Skin Tumors
Gaydosik, A. M., Tabib, T., Geskin, L. J., Bayan, C.-A. Y., Conway, J. F., Lafyatis, R., & Fuschiotti, P. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0148 · Cited by 140 · see citing works
Kouidhi, S., Elgaaïed, A. B., & Chouaı̈b, S. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00270 · Cited by 138 · see citing works
Hossain, M. A., Liu, G., Dai, B., Si, Y., Yang, Q., Wazir, J., Birnbaumer, L., & Yang, Y. (2020) · Medicinal Research Reviews · doi:10.1002/med.21727 · Cited by 136 · see citing works
Fusobacterium nucleatum, inflammation, and immunity: the fire within human gut
Bashir, A., Miskeen, A. Y., Hazari, Y., Asrafuzzaman, S., & Fazili, K. M. (2015) · Tumor Biology · doi:10.1007/s13277-015-4724-0 · Cited by 133 · see citing works
Haller, M. J., Long, S. A., Blanchfield, L., Schatz, D., Skyler, J. S., Krischer, J. P., Bundy, B. N., Geyer, S. M., WARNOCK, M. V., Miller, J. L., et al. (2019) · Diabetes · doi:10.2337/db19-0057 · Cited by 134 · see citing works
Zhang, Z., Chen, L., Chen, H., Zhao, J., Li, K., Sun, J., & Zhou, M. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2022.104207 · Cited by 133 · see citing works
Understanding the Biology of Antigen Cross-Presentation for the Design of Vaccines Against Cancer
Fehres, C. M., Unger, W. W. J., García-Vallejo, J. J., & van Kooyk, Y. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00149 · Cited by 133 · see citing works
Radiation Exposure Induces Inflammasome Pathway Activation in Immune Cells
Stoecklein, V. M., Osuka, A., Ishikawa, S., Lederer, M. R., Wanke-Jellinek, L., & Lederer, J. A. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1303051 · Cited by 132 · see citing works
LILRB4 suppresses immunity in solid tumors and is a potential target for immunotherapy
Sharma, N., Atolagbe, O. T., Ge, Z., & Allison, J. P. (2021) · The Journal of Experimental Medicine · doi:10.1084/jem.20201811 · Cited by 131 · see citing works
- Authors
- Crespo, J., Sun, H., Welling, T. H., Tian, Z., & Zou, W.
- Affiliations
- University of Michigan (US)
- University of Science and Technology of China (CN)
- Corresponding author
- Tian, Zhigang
- Zou, Weiping
- Venue
- Current Opinion in Immunology
- Publisher
- Elsevier BV
- Published
- 2013-04
- Volume
- 25
- Issue
- 2
- Pages
- 214-221
- ISSN
- 0952-7915 (ISSN-L)
- PMC
- PMC3636159
- OpenAlex
- W2050558251
- Cited by
- 752
- References
- 77
- Citations by year
- 2026: 32 · 2025: 67 · 2024: 74 · 2023: 76 · 2022: 73 · 2021: 80 · 2020: 63 · 2019: 59 · 2018: 61 · 2017: 52 · 2016: 42 · 2015: 42 · 2014: 23 · 2013: 8
- FWCI
- 3.34
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Current Opinion in Immunology (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health (5t32ai007413-32)
- National Cancer Institute (R01CA123088, R01CA152470, R01CA156685, K08CA151414, R01CA099985)
- National Institute of Allergy and Infectious Diseases (T32-AI-007413)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- T cell anergy, T cell exhaustion, T cell senescence, T cell stemness, tumor microenvironment, tumor-associated antigens, immune evasion, immunosuppression, cancer immunotherapy
- MeSH terms
- Animals, Humans, Neoplasms, Stem Cells, T-Lymphocytes, Cellular Senescence, Clonal Anergy, Tumor Microenvironment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Claims read by deepseek-v4.1-flash under definition version 3 (extract-v3) on 2026-10-06.
Classified by jev-1.13-20260917 (gold-guideline-v0.2) on 2026-10-06.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review